Últimas noticias sobre CareMax (OTC:CMAXQ) Bolsa

CareMax Inc is a technology-enabled care platform providing value-based care and chronic disease management to seniors. It operates various owned medical centers that offer a comprehensive suite of healthcare and social services and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States.

CareMax Inc

News

Trading Ideas

TMDE

TMD Energy Shares Halted, News Pending

Oppenheimer analyst Martin Yang maintains QuickLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUIK#NASDAQ">QUIK</a>) with a Outperform and lowers the price target from $13 to $11.

Price Target

Analyst Ratings

QUIK

Oppenheimer Maintains Outperform on QuickLogic, Lowers Price Target to $11

Wells Fargo analyst Sam Reid maintains Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) with a Equal-Weight and raises the price target from $65 to $73.

Wells Fargo Maintains Equal-Weight on Masco, Raises Price Target to $73

WIIM

VUZI

VUZI stock has given up its prior gain. Vuzix shares were trading higher after the company, along with Himax Technologies, announced its AR optical module will jointly debut at Display Week 2025.

Oppenheimer analyst Jeff Jones maintains Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) with a Outperform and lowers the price target from $21 to $20.

YMAB

Oppenheimer Maintains Outperform on Y-mAbs Therapeutics, Lowers Price Target to $20

Macro Economic Events

Market Summary

Economics

General

Benzinga Market Summary: S&P Roughly Flat At Open, AMD Rises On Buyback

Wells Fargo analyst Yanan Zhu maintains Metagenomi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) with a Overweight and lowers the price target from $20 to $16.

Wells Fargo Maintains Overweight on Metagenomi, Lowers Price Target to $16

Global

Charles Gasparino Posts On X "Scoop: Trade-tariff deals with Japan and South Korea said to be "close," according to me Wall Street sources close to the White House. Timing unclear. India deal as well though it has been throttled by the tensions with Pakistan..."

INVZ

INVZ stock has given up its prior gain. Innoviz Technologies shares were trading higher after the company reported better-than-expected Q1 financial results and issued FY25 sales guidance with its midpoint above estimates.

Wells Fargo analyst Yanan Zhu maintains Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Overweight and lowers the price target from $50 to $45.

ARCT

Wells Fargo Maintains Overweight on Arcturus Therapeutics, Lowers Price Target to $45

Oppenheimer analyst Michael Wiederhorn maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Outperform and lowers the price target from $600 to $400.

Oppenheimer Maintains Outperform on UnitedHealth Group, Lowers Price Target to $400

ALLO

Allogene Therapeutics shares are trading lower after the company reported Q1 financial results. Also, Baird and Oppenheimer lowered their respective price targets on the stock.

Cruise line stocks are historically among the strongest seasonal performers in the S&amp;P 500 heading into the second half of May, with Royal Caribbean Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>), Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) and Carnival Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) averaging double-digit returns over a <a href="https://www.benzinga.com/topic/seasonality">three-week window.</a>
Historical data from Seasonax platforms shows that from May 14 to early June, these three stocks have consistently outperformed over the past decade, with average gains north of 10%. 
Among all S&amp;P 500 constituents, they rank at the very top for late-spring seasonality. Seasonal strength is typically fueled by ramping summer demand, strong forward bookings, and an uptick in consumer travel spending ahead of peak vacation months.
Here are the top five S&amp;P 500 stocks by average return in a three-week period starting from May 14:
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Stock</th>
<th>Avg. Return (Last 10 years)</th>
<th>Max Profit</th>
<th>Max Loss</th>
<th>Win Rate</th>
<th>Pattern Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norwegian Cruise Line</td>
<td>+13.75%</td>
<td>+149.63%</td>
<td>-6.59%</td>
<td>5/10</td>
<td>May 14 – Jun 7</td>
</tr>
<tr>
<td>Caesars Entertainment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>)</td>
<td>+11.98%</td>
<td>+102.49%</td>
<td>-0.11%</td>
<td>9/10</td>
<td>May 14 – Jun 6</td>
</tr>
<tr>
<td>Royal Caribbean</td>
<td>+11.52%</td>
<td>+113.71%</td>
<td>-7.48%</td>
<td>6/10</td>
<td>May 14 – Jun 6</td>
</tr>
<tr>
<td>Carnival Corp.</td>
<td>+11.28%</td>
<td>+103.02%</td>
<td>-5.19%</td>
<td>5/10</td>
<td>May 14 – Jun 6</td>
</tr>
<tr>
<td>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)</td>
<td>+10.69%</td>
<td>+88.13%</td>
<td>-4.95%</td>
<td>8/10</td>
<td>May 14 – Jun 7</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Source: Seasonax</figcaption></figure>
<h3 class="wp-block-heading">RCL Sees Strong Summer Bookings</h3>
In a note from late April, Goldman Sachs analyst Lizzie Dove pointed to a strong reversal in booking momentum despite broader macro uncertainty and uneven travel data across the sector.
April bookings at RCL exceeded the same month last year, while close-in bookings remained firm. 
The company also reported stronger-than-usual onboard spending and pre-cruise purchases. Forward bookings for 2026 were tracking in line with 2024 levels but at higher prices—a sign of pricing power in an inflation-sensitive market.
With approximately 86% of the 2025 cruise calendar already booked, Dove's team raised their estimates and lifted the stock's price target from $245 to $260. However, they retained a slightly more cautious tone in 2026, pending more clarity on consumer resilience.
Since hitting tariff-driven lows on April 9, shares of RCL have surged 50% through mid-May —more than twice the gain of the S&amp;P 500. CCL shares matched the performance during the same period. 
<h3 class="wp-block-heading">NCLH Flags Demand Softness Amid Macro Pressures</h3>
In contrast, Norwegian Cruise Line is facing a different set of conditions. 
In early May, Bank of America analyst Andrew Didora highlighted NCLH as the first in the group to show softness in its 12-month forward-booked position.
While this wasn't viewed as unexpected—given the macro backdrop, consumer sentiment, and fare discounts introduced under the Oceania brand—it raised questions about forward pricing discipline across the cruise industry. Didora added that weakening demand isn't isolated to NCLH, and other operators may be seeing similar dynamics. 
BofA cut its 2025 and 2026 EPS forecasts for NCLH by 3% and 2%, now expecting $2.07 and $2.53, respectively. It revised the price objective down from $23 to $20 while maintaining a Neutral rating on concerns around leverage and top-line pressures.
Shares of NCLH have rallied 36% since April lows, underperforming versus peers. 
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45298562/chipmakers-enter-bullish-seasonal-window-5-stocks-that-could-outperform">Chipmakers Enter Bullish Seasonal Window: 5 Stocks That Could Outperform </a></li>
</ul>
Photo: Shutterstock

Travel

ENPH

NCLH

Cruises Set Sail Ahead Of Summer Boom: These 3 S&P 500 Stocks Show Strongest Late-May Seasonality

Oppenheimer analyst Jay Olson maintains Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Outperform and lowers the price target from $15 to $13.

Oppenheimer Maintains Outperform on Inovio Pharmaceuticals, Lowers Price Target to $13

Wells Fargo analyst Yanan Zhu maintains Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Equal-Weight and lowers the price target from $1.5 to $1.

ADAP

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Lowers Price Target to $1

Wells Fargo analyst Eva Fortea Verdejo maintains ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) with a Overweight and lowers the price target from $16 to $13.

ITOS

Wells Fargo Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $13

CREX

Creative Realities shares are trading higher. The company reported Q1 financial results.

Oppenheimer analyst Timothy Horan initiates coverage on Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Outperform rating and announces Price Target of $15.

Initiation

Core Scientific, Inc. - Class A Common Stock

CORZ

Oppenheimer Initiates Coverage On Core Scientific with Outperform Rating, Announces Price Target of $15

Wells Fargo analyst Larry Biegelsen maintains Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) with a Equal-Weight and lowers the price target from $1.29 to $0.68.

HYPR

Wells Fargo Maintains Equal-Weight on Hyperfine, Lowers Price Target to $0.68

The Tampa Bay Lightning have entered into a multi-year media rights agreement with Scripps Sports, which will make it easier than ever for fans throughout the Tampa Bay area to watch Lightning hockey games for free beginning with the start of the 2025-26 NHL season this fall.
This new agreement allows The E.W. Scripps Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSP#NASDAQ">SSP</a>) to produce and distribute all preseason, regular season and first-round playoff Lightning games that are not allocated exclusively to national broadcasts.
 &nbsp;

Comments

CareMax

Noticias

Últimas noticias sobre CareMax (OTC:CMAXQ) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL